Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy

On June 7, 2021 Alligator Bioscience (Nasdaq Stockholm: ATORX) reported that the scientific journal Expert Opinion on Biological Therapy has published an article by scientists at Alligator Bioscience, reviewing the field of CD40 agonistic antibodies (Press release, Alligator Bioscience, JUN 7, 2021, View Source [SID1234583634]). The article provides an overview of the CD40 agonistic antibodies in clinical development and the current challenges and opportunities for this important class of immuno-oncology drugs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy

Journal: Expert Opinion on Biological Therapy

Authors: Karin Enell Smith et al

"We’re very pleased to have this peer-reviewed article prepared by Alligator’s scientists published. It highlights the promising role of CD40 agonists in immuno-oncology and explains how Alligator’s CD40 agonist, mitazalimab, has best in class potential," said Søren Bregenholt, CEO of Alligator Bioscience. "We’re now looking forward to initiating the OPTIMIZE-1 Phase II study designed to assess the clinical efficacy of mitazalimab combined with chemotherapy in patients with metastatic pancreatic cancer."

Mitazalimab is an agonistic – or stimulatory – antibody that targets CD40, a receptor on dendritic cells, which are the cells that instruct T cells to kill cancer cells. Mitazalimab activates CD40 enabling dendritic cells to effectively stimulate the immune system directing T cells to selectively attack the tumor. This addresses one of the key mechanistic needs in immuno-oncology and highlights the potential of CD40 as a target to treat patients with metastatic cancer. Mitazalimab’s favorable efficacy-safety profile demonstrated in previous phase I studies, makes it ideal for combination with standard of care treatments such a chemotherapy, check-point inhibitors or cancer vaccines.